Mass Drug Pricing Fraud Turns on Aggregate ‘Loss of Value’ Evidence

Business Valuation UpdateVol. 16 No. 3
Legal and Court Case Update
March 2010

Access the Full Article

This article is available with a subscription to any of these products:
Already a subscriber?  Login
This article is also available for purchase. (1,056 words)   Add to Cart >>
Need help? Contact us:
1-503-479-8200 ext 2 or sales@bvresources.com
2834 Pharmaceutical Preparations
325412 Pharmaceutical Preparation Manufacturing
fraud
In re Zyprexa Products Liability Litigation
2009 WL 4260857 (E.D.N.Y)
December 1, 2009
US
Federal Court
New York
United States District Court
Allan Andrew Thoen, Andrew Kirkendall, Andrew R Rogoff, Douglas T Miracle, Elizabeth Williams, Fletcher Vines Trammell, George A Lehner, John F Brenner, Kenneth Camp Bailey, Leslie B LaMacchia, Lisa A Reppeto, Matthew J Hamilton, Michael W Perrin, Nevil
Meredith Rosenthal (plaintiffs)
Weinstein

Summary

Massive claims of drug-overpricing turn on expert evidence of aggregate “loss of value” to Medicaid and other third-party payers.

See Also

In re Zyprexa Products Liability Litigation

Full Text of Court Cases
December 1, 2009

Massive claims of drug-overpricing turn on expert evidence of aggregate “loss of value” to Medicaid and other third-party payors.